|
Socio-demographic and lifestyle factors
| | |
|
Age (years, mean, SD)
|
395
|
60.7 (6.9)
|
|
Caucasian (%)
|
385
|
91.9
|
|
Education (%)
|
385
| |
|
High school degree or less
| |
16.4
|
|
Some college
| |
30.9
|
|
College degree
| |
23.9
|
|
Post graduate
| |
28.8
|
|
Household income (%)
|
365
| |
|
< $50,000
| |
18.3
|
|
$50,000—< $75,000
| |
20.3
|
|
≥ $75,000
| |
61.4
|
|
Married or living with a partner (%)
|
395
|
82.5
|
|
Smoking (%)
|
385
| |
|
Never smoker
| |
62.5
|
|
Former smoker
| |
32.7
|
|
Current smoker
| |
6.8
|
|
Charlson Comorbidity Index (%)
|
394
| |
|
No comorbidities
| |
16.2
|
|
Any comorbidities
| |
26.2
|
|
Missing
| |
57.6
|
|
Prostate cancer- and surgery-related factors
| |
|
Clinical T1 stage (%)
|
381
|
78.5
|
|
Pathological stage (%)
|
389
| |
|
T2
| |
11.1
|
|
T3
| |
88.9
|
|
Pre-surgical prostate-specific antigen concentration (ng/mL, mean, SD)
|
393
|
6.3 (4.6)
|
|
Blood loss during surgery (mL, mean, SD)
|
358
|
246.3 (203.3)
|
|
Neurovascular bundle preservation (%)
|
351
| |
|
Non-nerve sparing
| |
19.4
|
|
Unilateral neurovascular bundle spared
| |
15.4
|
|
Bilateral nerve sparing
| |
65.2
|
|
Surgical procedure (%)
|
365
| |
|
Minimally-invasive (robotic and laparoscopic)
| |
92.3
|
|
Open
| |
7.7
|
|
Bladder reconstruction
|
364
|
53.0
|
|
BPH-related factors
| |
|
Prostate size (grams, mean, SD)
|
288
|
43.5 (16.6)
|
|
IPSS score at baseline (mean, SD)
|
249
|
8.6 (6.7)
|
|
BPH medication use at baseline (%)
|
395
|
13.2
|
|
α-blocker use
| |
10.4
|
|
5α-reductase inhibitor (and α-blocker) use
| |
2.8
|
|
Urinary and sexual function-related factors
| |
|
Reported Kegel exercises
| | |
|
5 weeks post-surgery
|
358
|
67.3
|
|
12 months post-surgery
|
332
|
31.3
|
|
ED medication or device use (%)
| | |
|
Baseline
|
365
|
4.8
|
|
5 weeks post-surgery
|
365
|
30.1
|
|
12 months post-surgery
|
336
|
18.2
|
